Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of Graph Search.
Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, andpresent antigens to T lymphocytes. They also generate cytokine and chemokine gradients thatregulate immune cell trafficking, activation, and function. Monocyte-derived DCs (moDCs)pulsed with tumor antigens have been used as a platformfor therapeutic vaccination in cancer.However, in spite of significant development and testing, antigen-loaded moDCs have deliveredmixed clinical results. In my thesis, I have worked on a new DC therapy approach thatuses a population named DC progenitors (DCPs) engineered to produce two immunostimulatorycytokines, IL-12 and FLT3L. In the absence of antigen loading, cytokine-armed DCPsefficiently differentiated into conventional type I DCs (cDC1) and inhibited tumor growth inmelanoma and autochthonous liver cancer models. Tumor response to DCP therapy involvedsynergy between IL-12 and FLT3L and was associated with massive effector T cell infiltrationand NK cell activation, robust M1-like macrophage programming, and ischemic tumor necrosis.Mechanistically, anti-tumor immunity was dependent on endogenous cDC1 expansionand interferon-y (IFN-y) production and signaling, but did not require CD8+ T cell cytotoxicity.In one application, cytokine-armed DCPs synergized with antigen-specific CAR-T cells toeradicate intracranial gliomas in mice.
Bart Deplancke, Guido Van Mierlo, Jorieke Weiden